Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 4, 2007, Pages 366-376

  Varas Lorenzo, Cristina ^a   Maguire, Andrew ^a   Castellsague, Jordi ^a   Perez Gutthann, Susana ^a  

^a PFIZER INC   (United States)

Author keywords

Gastrointestinal and cardiovascular safety; NSAIDs; Risk benefit

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTHRITIS; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG FATALITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PEPTIC ULCER; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SIMULATION; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COMPUTER SIMULATION; CORONARY DISEASE; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NAPROXEN; PEPTIC ULCER; POPULATION SURVEILLANCE; PYRAZOLES; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; UNITED STATES;

EID: 34247512469     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1299     Document Type: Article

References (47)

1. Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2-specific inhibitors. Am J Med 2001; 110(3A): 6S-12S.
2. Hernéndez-Díaz S, García-Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099.
3. Hernéndez-Díaz S, García-Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 110(3A): 20S-27S.
4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib, and naproxen in patients with rheumatoid arthritis. N EngI J Med 2000; 343: 1520-1528.
6. Schnitzer TJ, Burmester GR, Mysler E, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674.
7. Ramey DR, Watson DJ, Yu Ch, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21(5): 715-722.
8. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs. The relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S.
9. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 1468-1471.
10. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997; 17: 277-289.
11. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. JPET 1999; 289(2): 735-741.
12. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenae-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-430.
13. FDC reports. Merck Arcoxia at ACR: data suggest thrombotic proffle similar to Vioxx. Pink Sheet 2001; 63(48): 9.
14. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-684.
15. Bresalier RS, Sandler RS, Quart H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
16. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-1091.
17. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-1492.
18. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
19. Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex [online]. Available from URL: http://www.pfizer.com/pfizer/are/ investors_releases/2004pr/mn_2004_1217.jsp.
20. Karnon J. Alternative decision modelling techniques for the evaluaton of health care technologies: Markov processes versus discrete event simulation. Health Econ 2003; 12: 837-848.
21. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94. Hyattsville, MD: U.S. Department of Health and Human Services; 1994.
22. Adams PF, Marchesi L. Current estimates from the National Health Interview Survey, 1994. National Center for Health Statistics. Vital Health Stat 10(193): 1995.
23. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272-281.
24. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22(3): 312-318.
25. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25(1): 40-43.
26. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol; 22(Suppl. A): 6A-13A.
27. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979; 44(1): 53-59.
28. Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence following stroke. The Framingham study. Stroke 1982; 13(3): 290-295.
29. Lemer DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111(2): 383-390.
30. Pérez Gutthann S, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8(1): 18-24.
31. Hasselgren G, Carlsson J, Lind T, et al. Risk factors for rebleeding and fatal outcome in elderly patients with acute peptic ulcer bleeding. Eur J Gastroen Hepatol 1998; 10(8): 667-672.
32. García Rodríguez LA, Ruigómez A, Hasselgren G. et al. Comparison of mortality from peptic ulcer bleed between patients with or without peptic ulcer antecedents. Epidemiology 1998; 9(4): 452-456.
33. Ruigómez A, García Rodríguez LA, Hasselgren G, et al. Over-all mortality among patients surviving an episode of peptic ulcer bleeding. J Epidemiol Community Health 2000; 54(2): 130-133.
34. Death rates from 282 Selected Causes by 5-Year Age Groups, Race, and Sex: United States, 1979-98. National Center for Health Statistics. Data Warehouse. http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/ gmwk292a.htm
35. Hernández-Díaz S, Varas-Lorenzo C, García-Rodríguez LA. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic & Clinic Pharmacol & Tox 2006; 98: 266-274.
36. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751-1756.
37. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002; 325: 624-627.
38. Mohadjer L, Montaquila J, Waksberg J. NHANES III: Weighting and Estimation Methodology. NCHS Executive Summary. National Center for Health Statistics: Hyattsville, MD, 1996.
39. Urban N, Drescher C, Etzioni R, et al. Use of stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997; 18: 251-270.
40. Moride Y, Ducruet T, Reynolds MW, et al. Non-steroidal anti-inflammatory drug use: impact of risk factors for gastropathy on prescribing practices. Pharmacoepidemiol Drug Safe 2002; 11: S128.
41. MacDonald TM, Moram SV, Goldstein JL, et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52(9): 1265-1270.
42. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important. Am J Med 2003; 115(9): 715-720.
43. Bérard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 2000; 27(7): 1648-1655.
44. Rincón I, William K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745.
45. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
46. Heerdink ER, Leufkens HG, Hering RMC, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern med 1998; 158: 1108-1112.
47. García-Rodríguez LA, Hernández-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14: 240-246.